Comprehensive analysis of mutational patterns has demonstrated that roughly 20 percent of breast tumors showed a mutational signature that was characteristic of BRCA mutations. Even without BRCA mutations, the mutational pattern suggests such tumors might have the same sensitivity to poly ADP-ribose polymerase (PARP) inhibitors as tumors with detectable BRCA mutations.